NEW YORK–(BUSINESS WIRE) December 14, 2021 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Xeljanz® / Xeljanz® XR (tofacitinib) for…Original Article
U.S. FDA Approves Pfizer’s Xeljanz (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
